KIT and melanoma: - Melanoma-specific “exosome signature” characterized by TYRP2, VLA-4, HSP70) and MET- Exosome treatment → °two-fold increase in vasculogenic c-Kit+Tie2+ progenitors in BMN (<-> other HSPCs not affected)- Treatment with B16-F10, but not B16-F1, exosomes increased Met in vasculogenic (Tie2+) and LSK HSPCs in circulation but not in the BMN- CD45−c-Kitlow/+Tie2+ circulating HSPCs in metastatic melanoma patients express high MET receptor